Publication at Faculty of Medicine in Hradec Králové |
2012
Abstract
The author presents his first personal experience with golimumab, a new monoclonal antibody blocking TNF alfa, on a case of advanced ankylosing spondylitis. More detailed insight into the pathogenesis of inflammatory rheumatic diseases enabled introduction of biologic therapy in last decade and this therapeutic hit into the immunopathologic process on a cytokine level is bound to mighty clinical effect and positive impact on rheumatic patients' quality of life.